The 2022 aggregate production quotas of dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, amphetamine sulfate, dexmethylphenidate, lisdexmethylphenidate , and methylphenidate were NOT increased for 2023. DEA said the manufacturers reported the 2022 supply was enough for domestic and export purposes. But that does not factor increases in export activities from 2022-2023.
"
Issue: DEA received comments from five DEA-registered manufacturers regarding 10 different schedule I and II controlled substances, requesting that the proposed APQ for d-amphetamine (for conversion), dexmethylphenidate (for conversion), dexmethylphenidate (for sale), isomethadone, lisdexamfetamine, methylphenidate (for conversion), methylphenidate (for sale), noroxymorphone (for conversion), oripavine, and oxymorphone (for conversion) be established at sufficient levels to allow for manufacturers to meet medical and scientific needs.
DEA Response: DEA considered the comments for these specific controlled substances and determined that an increase from DEA's proposed APQs are not necessary at this time, as reflected below in the section titled Determination of 2023 Aggregate Production Quotas and Assessment of Annual Needs"
My math says there is going to be 15+% shortage for all of 2023, which might get worse in 2024.